Interleukins in Cancer Therapy: Rationale and Current Status

Leslie Oleksowicz, Joseph A. Sparano, Kevin O’Boyle, Usha Venkatraj, Peter H. Wiernik, Janice P. Dutcher

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The interleukins function as intercellular hormones, and have the capacity to alter the activity of a target cell population. Immunotherapy with interleukin-2 (IL-2) constitutes a new treatment strategy for malignancies otherwise not responsive to traditional cytotoxic chemotherapy. In advanced renal cell carcinoma, studies using high dose bolus IL-2 alone have resulted in mean objective response rates of approximately 15% (0 to 27%). Durable responses in some patients have translated into increased survival. With advanced melanoma, high dose bolus IL-2 therapy alone produces response rates ranging from 21 to 24%, although other studies using lower doses, different drug preparations or different schedules have resulted in lower response rates. Studies are now under way using IL-2 in combination with interferons, cytotoxic chemotherapy, monoclonal antibodies and tumour infiltrating lymphocytes in an attempt to enhance the biological activity of IL-2. Another promising use of IL-2 therapy is in the treatment of acute leukaemia. Several small studies have shown benefit of IL-2 given to patients in early relapse, leading to normalisation of bone marrow and prolonged remissions in some patients. IL-2 is currently being investigated as a post-transplant adjuvant strategy in patients undergoing bone marrow transplantation for haematological malignancies. Newly characterised interleukins such as IL-4 and IL-6 have demonstrated preclinical antitumour and immunoenhancing properties, resulting in their recent introduction into clinical trials. Additionally, IL-6 has demonstrated thrombopoietic enhancing activity in early clinical trials and has a potential application in ameliorating thrombocytopenia associated with myeloablative chemotherapy. In summary, these interleukins have proven to be effective additions to treatment strategies in oncology.

Original languageEnglish (US)
Pages (from-to)271-281
Number of pages11
JournalClinical Immunotherapeutics
Volume1
Issue number4
DOIs
StatePublished - 1994

Fingerprint

Interleukins
Interleukin-2
Neoplasms
Therapeutics
Drug Therapy
Interleukin-6
Clinical Trials
Tumor-Infiltrating Lymphocytes
Drug Compounding
Health Services Needs and Demand
Hematologic Neoplasms
Bone Marrow Transplantation
Renal Cell Carcinoma
Interleukin-4
Thrombocytopenia
Immunotherapy
Interferons
Melanoma
Appointments and Schedules
Leukemia

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

Oleksowicz, L., Sparano, J. A., O’Boyle, K., Venkatraj, U., Wiernik, P. H., & Dutcher, J. P. (1994). Interleukins in Cancer Therapy: Rationale and Current Status. Clinical Immunotherapeutics, 1(4), 271-281. https://doi.org/10.1007/BF03259253

Interleukins in Cancer Therapy : Rationale and Current Status. / Oleksowicz, Leslie; Sparano, Joseph A.; O’Boyle, Kevin; Venkatraj, Usha; Wiernik, Peter H.; Dutcher, Janice P.

In: Clinical Immunotherapeutics, Vol. 1, No. 4, 1994, p. 271-281.

Research output: Contribution to journalArticle

Oleksowicz, L, Sparano, JA, O’Boyle, K, Venkatraj, U, Wiernik, PH & Dutcher, JP 1994, 'Interleukins in Cancer Therapy: Rationale and Current Status', Clinical Immunotherapeutics, vol. 1, no. 4, pp. 271-281. https://doi.org/10.1007/BF03259253
Oleksowicz, Leslie ; Sparano, Joseph A. ; O’Boyle, Kevin ; Venkatraj, Usha ; Wiernik, Peter H. ; Dutcher, Janice P. / Interleukins in Cancer Therapy : Rationale and Current Status. In: Clinical Immunotherapeutics. 1994 ; Vol. 1, No. 4. pp. 271-281.
@article{030ad531a52d4cfdb8060847b5031197,
title = "Interleukins in Cancer Therapy: Rationale and Current Status",
abstract = "The interleukins function as intercellular hormones, and have the capacity to alter the activity of a target cell population. Immunotherapy with interleukin-2 (IL-2) constitutes a new treatment strategy for malignancies otherwise not responsive to traditional cytotoxic chemotherapy. In advanced renal cell carcinoma, studies using high dose bolus IL-2 alone have resulted in mean objective response rates of approximately 15{\%} (0 to 27{\%}). Durable responses in some patients have translated into increased survival. With advanced melanoma, high dose bolus IL-2 therapy alone produces response rates ranging from 21 to 24{\%}, although other studies using lower doses, different drug preparations or different schedules have resulted in lower response rates. Studies are now under way using IL-2 in combination with interferons, cytotoxic chemotherapy, monoclonal antibodies and tumour infiltrating lymphocytes in an attempt to enhance the biological activity of IL-2. Another promising use of IL-2 therapy is in the treatment of acute leukaemia. Several small studies have shown benefit of IL-2 given to patients in early relapse, leading to normalisation of bone marrow and prolonged remissions in some patients. IL-2 is currently being investigated as a post-transplant adjuvant strategy in patients undergoing bone marrow transplantation for haematological malignancies. Newly characterised interleukins such as IL-4 and IL-6 have demonstrated preclinical antitumour and immunoenhancing properties, resulting in their recent introduction into clinical trials. Additionally, IL-6 has demonstrated thrombopoietic enhancing activity in early clinical trials and has a potential application in ameliorating thrombocytopenia associated with myeloablative chemotherapy. In summary, these interleukins have proven to be effective additions to treatment strategies in oncology.",
author = "Leslie Oleksowicz and Sparano, {Joseph A.} and Kevin O’Boyle and Usha Venkatraj and Wiernik, {Peter H.} and Dutcher, {Janice P.}",
year = "1994",
doi = "10.1007/BF03259253",
language = "English (US)",
volume = "1",
pages = "271--281",
journal = "BioDrugs",
issn = "1173-8804",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - Interleukins in Cancer Therapy

T2 - Rationale and Current Status

AU - Oleksowicz, Leslie

AU - Sparano, Joseph A.

AU - O’Boyle, Kevin

AU - Venkatraj, Usha

AU - Wiernik, Peter H.

AU - Dutcher, Janice P.

PY - 1994

Y1 - 1994

N2 - The interleukins function as intercellular hormones, and have the capacity to alter the activity of a target cell population. Immunotherapy with interleukin-2 (IL-2) constitutes a new treatment strategy for malignancies otherwise not responsive to traditional cytotoxic chemotherapy. In advanced renal cell carcinoma, studies using high dose bolus IL-2 alone have resulted in mean objective response rates of approximately 15% (0 to 27%). Durable responses in some patients have translated into increased survival. With advanced melanoma, high dose bolus IL-2 therapy alone produces response rates ranging from 21 to 24%, although other studies using lower doses, different drug preparations or different schedules have resulted in lower response rates. Studies are now under way using IL-2 in combination with interferons, cytotoxic chemotherapy, monoclonal antibodies and tumour infiltrating lymphocytes in an attempt to enhance the biological activity of IL-2. Another promising use of IL-2 therapy is in the treatment of acute leukaemia. Several small studies have shown benefit of IL-2 given to patients in early relapse, leading to normalisation of bone marrow and prolonged remissions in some patients. IL-2 is currently being investigated as a post-transplant adjuvant strategy in patients undergoing bone marrow transplantation for haematological malignancies. Newly characterised interleukins such as IL-4 and IL-6 have demonstrated preclinical antitumour and immunoenhancing properties, resulting in their recent introduction into clinical trials. Additionally, IL-6 has demonstrated thrombopoietic enhancing activity in early clinical trials and has a potential application in ameliorating thrombocytopenia associated with myeloablative chemotherapy. In summary, these interleukins have proven to be effective additions to treatment strategies in oncology.

AB - The interleukins function as intercellular hormones, and have the capacity to alter the activity of a target cell population. Immunotherapy with interleukin-2 (IL-2) constitutes a new treatment strategy for malignancies otherwise not responsive to traditional cytotoxic chemotherapy. In advanced renal cell carcinoma, studies using high dose bolus IL-2 alone have resulted in mean objective response rates of approximately 15% (0 to 27%). Durable responses in some patients have translated into increased survival. With advanced melanoma, high dose bolus IL-2 therapy alone produces response rates ranging from 21 to 24%, although other studies using lower doses, different drug preparations or different schedules have resulted in lower response rates. Studies are now under way using IL-2 in combination with interferons, cytotoxic chemotherapy, monoclonal antibodies and tumour infiltrating lymphocytes in an attempt to enhance the biological activity of IL-2. Another promising use of IL-2 therapy is in the treatment of acute leukaemia. Several small studies have shown benefit of IL-2 given to patients in early relapse, leading to normalisation of bone marrow and prolonged remissions in some patients. IL-2 is currently being investigated as a post-transplant adjuvant strategy in patients undergoing bone marrow transplantation for haematological malignancies. Newly characterised interleukins such as IL-4 and IL-6 have demonstrated preclinical antitumour and immunoenhancing properties, resulting in their recent introduction into clinical trials. Additionally, IL-6 has demonstrated thrombopoietic enhancing activity in early clinical trials and has a potential application in ameliorating thrombocytopenia associated with myeloablative chemotherapy. In summary, these interleukins have proven to be effective additions to treatment strategies in oncology.

UR - http://www.scopus.com/inward/record.url?scp=2642686389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2642686389&partnerID=8YFLogxK

U2 - 10.1007/BF03259253

DO - 10.1007/BF03259253

M3 - Article

AN - SCOPUS:2642686389

VL - 1

SP - 271

EP - 281

JO - BioDrugs

JF - BioDrugs

SN - 1173-8804

IS - 4

ER -